content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001628048</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001831363</issuerCik>
        <issuerName>Terns Pharmaceuticals, Inc.</issuerName>
        <secFileNumber>001-39926</secFileNumber>
        <issuerAddress>
          <com:street1>1065 EAST HILLSDALE BLVD., SUITE 100</com:street1>
          <com:city>FOSTER CITY</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94404</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>650-525-5535 EXT.101</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Vivo Capital Surplus Fund VIII, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Cowen and Company, LLC</name>
          <address>
            <com:street1>599 Lexington Ave Floor 21</com:street1>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10022</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>8832</noOfUnitsSold>
        <aggregateMarketValue>66795.00</aggregateMarketValue>
        <noOfUnitsOutstanding>64651693</noOfUnitsOutstanding>
        <approxSaleDate>04/01/2024</approxSaleDate>
        <securitiesExchangeName>Nasdaq</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <acquiredDate>02/04/2021</acquiredDate>
        <natureOfAcquisitionTransaction>IPO Allocation</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>IPO Underwriter</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>8832</amountOfSecuritiesAcquired>
        <paymentDate>02/06/2021</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>04/01/2024</noticeDate>
        <planAdoptionDates>
          <planAdoptionDate>09/29/2023</planAdoptionDate>
        </planAdoptionDates>
        <signature>Jack Nielsen</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2871}]
text: 144
  0001628048
  XXXXXXXX
  LIVE
  0001831363
  Terns Pharmaceuticals, Inc.
  001-39926
  1065 EAST HILLSDALE BLVD., SUITE 100
  FOSTER CITY
  CA
  94404
  650-525-5535 EXT.101
  Vivo Capital Surplus Fund VIII, L.P.
  Director
  Common
  Cowen and Company, LLC
  599 Lexington Ave Floor 21
  New York
  NY
  10022
  8832
  66795.00
  64651693
  04/01/2024
  Nasdaq
  Common
  02/04/2021
  IPO Allocation
  IPO Underwriter
  N
  8832
  02/06/2021
  Cash
  Y
  04/01/2024
  09/29/2023
  Jack Nielsen